Displaying drugs 13751 - 13775 of 15202 in total
Efmitermant alfa
Efmitermant alfa, a locally-acting GDF/activin ligand trap, is under investigation in clinical trial NCT03124459 (Study of ACE-083 in Patients With Charcot-marie-tooth Disease).
Investigational
Axalimogene filolisbac
Axalimogene filolisbac is under investigation in clinical trial NCT02853604 (Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer).
Investigational
Glutazumab
Glutazumab is a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein exerting anti-diabetic effects.
Investigational
Neihulizumab
Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.
Investigational
Inlezifigene civaparvovec
Experimental
Rovoctocogene durparvovec
Experimental
Cevaretigene ritoparvovec
Experimental
Bevufenogene nofeparvovec
Experimental
Sesiclenegene cosaparvovec
Investigational
Peboctocogene camaparvovec
Investigational
Aguracingene cadoparvovec
Investigational
Laruparetigene zovaparvovec
Investigational
Lixmabegagene relduparvovec
Lixmabegagene relduparvovec, formerly known as LYS-GM101, is a recombinant adeno-associated virus vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene (GBL1). It is under development for the treatment of GM1 gangliosidosis.
Experimental
Zorevunersen
Investigational
ALMB-0168
ALMB-0168 is a humanized connexin 43 (Cx43) monoclonal antibody being investigated for osteosarcoma.
Investigational
Mitsugumin-53
Investigational
AMT-130
Investigational
ANX-005
Investigational
Rovanersen
Investigational
Bidridistrogene xeboparvovec
Investigational
ATYR-1940
Investigational
AVXS-201
Withdrawn
SRP-6004
A recombinant AAVrh74 gene therapy expressing the dysferlin transgene under control of a muscle-specific promoter (rAAVrh74.MHCK7.DYSF.DV).
Investigational
BMN-052
Experimental
Withdrawn
BMN-053
Experimental
Withdrawn
Displaying drugs 13751 - 13775 of 15202 in total